Marginal. Modest. Incremental. That's how the FDA and members of its Oncologic Drugs Advisory Committee (ODAC) described the 1.6-month improvement in overall survival (OS) Eli Lilly and Co.'s necitumumab demonstrated in a pivotal trial as a first-line treatment for squamous NSCLC.